2021
Chapter 48 Malignancies in systemic lupus erythematosus
Ladouceur A, Tissera H, Clarke A, Ramsey-Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 48 Malignancies in systemic lupus erythematosus. 2021, 461-467. DOI: 10.1016/b978-0-12-814551-7.00048-9.ChaptersSystemic lupus erythematosusSLE patientsLupus erythematosusGeneral populationOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPotential reasonsLymphomaMalignancyPathophysiologyPopulationBreast
2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre Y, Clarke AE. Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. The Journal Of Rheumatology 2018, 45: 393-396. PMID: 29335347, PMCID: PMC5834350, DOI: 10.3899/jrheum.170652.Peer-Reviewed Original ResearchConceptsLung cancer risk factorsSystemic lupus erythematosusCancer risk factorsLung cancer casesLung cancer riskLung cancerRisk factorsSLE cohortDisease activityLupus erythematosusDrug exposureCancer casesCancer riskMcGill University Health CentreCumulative disease activityIncident lung cancerUniversity Health CentreCancer risk studiesInstitutional review boardHigher SLEDAIMedication exposureSLE controlsAdjusted effectHealth centersAdjusted model
2016
Breast cancer in systemic lupus
Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin P, Ginzler E, Romero-Diaz J, Peschken C, Jacobsen S, Hanly JG, Gordon C, Nived O, Yelin EH, Isenberg D, Rahman A, Bae SC, Joseph L, Witte T, Ruiz-Irastorza G, Aranow C, Kamen D, Sturfeldt G, Foulkes WD, Hansen JE, St Pierre Y, Raymer PC, Tessier-Cloutier B, Clarke AE. Breast cancer in systemic lupus. Lupus 2016, 26: 311-315. PMID: 27687028, PMCID: PMC5250552, DOI: 10.1177/0961203316664595.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBreast cancer riskAnti-dsDNA positivityBreast cancer casesBreast cancerCancer riskDisease activitySLE patientsHazard ratioCancer casesSLE samplesBreast cancer hazard ratioCancer hazard ratioCumulative disease activityFemale SLE patientsCase-cohort analysisCancer-free controlsCohort entrySLE durationClinical characteristicsSystemic lupusClinical factorsLupus erythematosusDrug exposureFamily historyChapter 46 Malignancies in Systemic Lupus Erythematosus
Tissera H, Clarke A, Goldman R, Gordon C, Hansen J, Bernatsky S. Chapter 46 Malignancies in Systemic Lupus Erythematosus. 2016, 411-415. DOI: 10.1016/b978-0-12-801917-7.00046-2.ChaptersSystemic lupus erythematosusSLE patientsGeneral populationLupus erythematosusOverall cancer incidence ratesHormone-sensitive cancersCancer incidence ratesRisk of breastDrug exposureIncidence rateProstate cancerHormonal changesHigh riskCancer profilePatientsCancerGenetic factorsErythematosusRiskPopulationPotential reasonsLymphomaMalignancyPathophysiologyBreast